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You are consulted by MB, a 58 year old lady. She is single 
and works as a manager with a leading advertising agency, 
keeping up with a lot of deadlines. During the visit, which was 
mainly related to some minor elbow complaint, you discover 
a raised blood pressure of 170/95 mmHg.  Subsequent visits 
confirm the raised blood pressure. She is known to suffer from 
dyslipidaemia, with a LDL-cholesterol of 4.5mmol/L and a total 
cholesterol of 6.3mmol/L. MB does not smoke.  How would you 
manage this case?
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Introduction
Hypertension is a common condition, and continues to be 
one of the most important causes of death and illness.1 At a 
public health level, it is expected to increase in frequency and 
affect 1.5 billion people by 2025.2 Hypertension is not only a 
disease in itself but also a strong risk factor for the development 
of cardiovascular disease ( Figure 1 and 2). In fact it is estimated 
to be implicated in 35% of all atherosclerotic events. 3
There is great benefit in treating hypertension which benefit 
should stimulate doctor and patient alike to strive for consistent 
control (Figure 3). Translated into NNT’s (Numbers Needed to 
Treat), this means that:
•	 In the presence of hypertension and additional risk 
factors, a 12 mmHg reduction in Systolic BP (SBP) over 
ten years will prevent one death for every 11 patients 
treated
•	 In the presence of cardiovascular disease or target organ 
damage, only nine patients would require such BP 
reduction to prevent death.4
For some reason, it seems that this benefit is not being 
exploited to the full and it is estimated that less than 10% of 
patients with hypertension have their blood pressure adequately 
controlled.5 
Definition
Blood pressure has a continuous (bell-shaped) distribution, 
with a continuous range of blood pressures from the lowest to the 
highest, with the majority in the middle.  Thus defining what is 
“raised blood pressure” is a matter of contention, compounded 
by the fact that there is a proportionate increase in risk of 
cardiovascular disease with increasing levels of blood pressure. 
Such risks both increase with age. 
Most guidelines regard 140/90 mmHg as the threshold 
above which one can use the term hypertension. In special 
circumstances which are deemed to be at high risk of 
cardiovascular events, namely diabetes, chronic kidney disease 
or in the context of secondary prevention of cardiovascular 
disease, this threshold is lowered to 130/80 mmHg. The USA 
guidelines of 2003 (JNC 7) have complicated the debate further 
by using the term “pre-hypertension”.6 However this adds no 
benefit to the management; on the other hand it may cause 
undue anxiety in patients who are not hypertensive.
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Once hypertension is confirmed, as is the case with our 
patient MB, one can proceed to:
1. Exclude any identifiable causes of the raised blood 
pressure (secondary hypertension).
2. Look out for concomitant cardiovascular disease and in 
the absence of a past history of cardiovascular events (as 
is the case with MB) carry out cardiovascular disease risk 
assessment.
3. Explain to the patient what is happening and arrive to an 
agreed management plan.
4. Offer treatment in a holistic way by using non-
pharmacological as well as pharmacologic treatment. The 
treatment should be aimed at lowering the blood pressure 
as well as lowering the cardiovascular risk of the patient 
as much as possible.
5. Offer a follow-up service which is acceptable to the 
patient.
Essential vs Secondary Hypertension
Of all patients diagnosed with hypertension, 95% fall in 
the category of essential (or idiopathic) hypertension, while 
5% will fall in the category of secondary hypertension.  In the 
latter category there is usually a well-defined disease process 
or contributory factor which would raise the blood pressure 
(Table 1). Over the last few years, there has been increasing 
awareness about the importance of the Renin-Angiotensin 
System (RAS) as the mechanism for essential hypertension. This 
hormonal axis even contributes to the differences seen between 
races in the expression of hypertension, response to treatment 
regimens and potential complications.7
The problem is how to identify the patients who will fall 
in each category. Many guidelines quote age as an important 
determinant; the younger the patient, the higher the probability 
of secondary hypertension.  While this is certainly true, problems 
arise in defining the cut-off age limit, and what to do with 
patients who are close to this age limit.
A more pragmatic approach involves using age as an 
important guiding tool but aiding oneself with a good systemic 
enquiry and general examination, especially in the first visit. 
Besides reassuring the patient, this will help guide the clinician 
to focus on the necessary investigations. As a routine, the 
European Society of Hypertension (ESH)8 suggests the following 
baseline investigations in all hypertensive patients:
•	 ECG
•	 Complete blood count
•	 Serum electrolytes, creatinine, liver function tests
•	 Fasting lipid profile and fasting plasma glucose
•	 Urine analysis
The ESH guidelines go even further and suggest that each 
hypertensive patient should have an echocardiogram and carotid 
ultrasound. However, this may not be practical, and is often 
reserved as second line investigations in cases with specific 
signs and symptoms.
Cardiovascular risk assessment
Following the initial diagnostic work-up, the cardiovascular 
risk of the patient may be calculated. As is well known, the 
more risk factors present, the higher is the risk of developing 
cardiovascular disease, their effect being synergistic.
The aim of carrying this risk assessment is twofold, as it:
•	 Allows proper evaluation and tailoring of treatment to the 
individual.
•	 Can be used as an educational tool, motivating the patient 
to improve his position with regard to risk.
There are various charts available, the two most commonly 
used being the SCORE charts and charts derived from the 
Framingham cohort. Both use systolic blood pressure as an 
inex, as this has been shown to be an important determinant 
of cardiovascular risk.9
Certain situations are deemed high risk by definition.  These 
are listed below:
•	 Diabetes (coined as coronary disease equivalent for 
the first time by the National Cholesterol Education 
Programme of the USA)10
•	 Chronic kidney disease
Figure 2: Hypertension and Mortality,
 adapted from Br Med J 1959; 1:1361
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Figure 1: Hypertension and risk of Cardiovascular 
 Disease, adapted from BMJ 2001; 322:977-80
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•	 Familial hypercholesterolaemia and related inherited 
disorders
•	 Past history of cardiovascular disease (e.g transient 
ischaemic attack, cerebrovascular accident)
•	 Associated clinical condition (e.g. peripheral vascular 
disease).
Admittedly, these risk estimation charts are not complete, 
and although they contain a relation of the major risk factors 
related to BP (age, systolic blood pressure level, smoking, gender 
and cholesterol level), they have certain well-noted limitations 
– they tend to underestimate the risk in younger patients and do 
not take into consideration other risk factors such as sedentary 
lifestyle, family history and obesity. Besides, they do not address 
the variation in risk between different ethnic groups. 
Some guidelines stratify patients according to blood pressure 
levels and number of risk factors present  (JNC 7 and ESH). 
However, they are often rather cumbersome to use and not 
quite patient-friendly.
Explanation to patient and choosing 
an agreed management plan
Due to the poor control of hypertension, this step is 
very important, since it will definitely motivate the patient. 
Admittedly, with a busy clinic, clinicians can easily fall in the 
trap of “dishing out” the fanciest drug of the moment, omitting 
to explain why the patient needs to be treated and why the 
particular drug was chosen.
It is estimated that up to 50% of patients do not abide by 
their treatment schedule.  Benson and Britten have highlighted 
the fact that there are a variety of reasons for not taking 
treatment.11  Contrary to what many doctors think, side effects 
are not the only reason for not taking prescribed medication. 
In one study, only one out of 38 patients interviewed declared 
that he/she was taking treatment for the benefits related to 
lowering blood pressure.
It is important to consider also the practical side of treatment 
namely that all guidelines are based on data obtained in 
trial settings. Targets set are difficult to achieve even in trial 
settings; in the recent ASCOT (Anglo-Scandinavian Clinical 
Outcomes Trial) study, only 32% of patients with diabetes and 
60% of patients without diabetes achieved the recommended 
targets.12
Extrapolating standards and treatment protocols from trials 
to everyday life seems a rational step; however this is often 
not so and here is where many guidelines may be regarding 
as failing.13  Financial aspects to treatment, motivation, lack 
of follow-up and inadequate communication between patient 
and clinician are possible causes why this extrapolation is not 
so easy to make.
Table 1: Causes and Contributory factors 
in Hypertension, adapted from JNC 7 and the 
European Hypertension Society Guidelines for 
Primary Care Physicians)
Causes
•  Drugs e.g. NSAIDS, OCP’s, steroids, 
 liquorice, sympathomimetics
•  Renal Disease – past present or family history
•  Renovascular disease
•  Phaeochromocytoma
•  Conn’s Syndrome
•  Coarctation of the aorta
•  Cushing’s syndrome
Contributory Factors
•  Overweight
•  Excess alcohol
•  Excess salt intake
•  Lack of exercise
•  Environmental Stress
NSAIDs – non-steroidal anti-inflammatory drugs 
OPC – oral contraceptive pill
Figure 4: A(B)CD for initial drug prescribing, 
 adapted from J Hum Hypertens 2004; 18:139-185
< 55 years of age or black > 55 years of age or black
A (or B) C or D
NB – A = ACEI or ARB; B = beta blocker; C =  Calcium 
channel blocker; D = Thiazide diuretic.  Recent evidence 
suggests that beta blockers are no longer regarded as first 
line therapy except in special circumstances (NICE 2006)
Figure 3: Event reduction with controlled hypertension,
 adapted from the J Hypertens 2003; 21:10
%
 e
ve
nt
 re
du
ct
io
n
Malta Medical Journal    Volume 18   Issue 03   October 2006 33
Treatment
The aim of treatment in the context of hypertension is to 
lower the overall cardiovascular risk, besides lowering the 
blood pressure.  There are two fundamental components to 
treatment:
•	 Lifestyle modifications 
 (Therapeutic Lifestyle Changes – TLCs)
•	 Pharmacological treatment.
Therapeutic Lifestyle Changes (TLCs)
The adoption of TLCs in the management plan will further 
increase the efficacy of any medications administered, lower 
further the cardiovascular risk of the patient, and most 
importantly empower the patient in the management of his 
disease. Admittedly, because of many social pressures, such 
TLCs are sometimes difficult to achieve. 
TLCs include:
1. Weight reduction in overweight or obese patients, 
aiming at a body mass index (BMI) of 20 – 25.
2. DASH (Dietary Approaches to Stop Hypertension) 
eating plan.  This type of eating plan is poor in fats and 
cholesterol and rich in potassium, calcium, magnesium, 
protein and fibre, through consumption of fruit, 
vegetables and low-fat dairy products.
3. Restricting dietary sodium is well known to reduce blood 
pressure effectively.
4. Physical activity.  Regular physical activity has been 
shown to lower significantly both systolic and diastolic 
blood pressure levels.14
5. Moderation in the consumption of alcohol
 Smoking cessation does not per se lower blood pressure, 
but it lowers the overall cardiovascular risk.
Table 2: Compelling indications and contraindications of the major drug classes
Drug Class Indications  Contraindications
Thiazide diuretics ISH, heart failure, elderly Gout; also associated with increased incidence 
  of diabetes especially when combined 
  with a beta blocker
  
ß-Blockers Angina, post-MI, possibly in heart  Asthma, COPD, PVD; also associated with
 failure at reduced dosage,  increased incidence of diabetes especially when
 tachyarrythmias, women  combined with a thiazide diuretic
 of child bearing age
Calcium channel blockers  ISH, elderly, Angina, PVD, 
(dihydropyridine group) pregnancy, hyperlipidaemia 
Calcium channel blockers  Angina, tachyarrythmias Heart block, heart failure, 
(non-dihydropyridine group)   never to be combined with beta blockers
ACEI Heart failure, post-MI,  Pregnancy, bilateral renal artery stenosis, PVD
 type I diabetic nephropathy, LVD, 
 hyperlipidaemia
ARBs Heart Failure, Diabetic nephropathy,  Pregnancy, PVD, renovascular disease
 ACEI induced cough, LV dysfunction, 
 hyperlipidaemia
a-Blockers Prostatic Hyperplasia;  Heart failure, orthostatic hypotension
 hyperlipidaemia; third line 
 add-on agent
COPD – Chronic Obstructive Pulmonary Disease; PVD – Peripheral Vascular Disease; LVD – Left Ventricular Dysfunction; 
ACEI – Angiotensin Converting Enzyme Inhibitor; ARB – Angiotensin Receptor Blocker; 
ISH – Isolated Systolic Hypertension; post-MI – post Myocardial Infarction  
Figure 5: The Birmingham Hypertension Square, 
 adapted from J Hum Hypertens 1998; 12: 761-3
Thiazides ß-Blockers
ACEI 
or ARB’s
Dihyrdropyridine
CCB’s
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Pharmacological Treatment
This can be divided into two major classes:
•	 Drug therapy to lower cardiovascular risk
•	 Drug therapy to lower blood  pressure.
Drugs lowering cardiovascular risk
Aspirin and statins are the two drug classes commonly 
used in this setting.  Aspirin has been well documented to 
prevent cardiovascular events in the context of secondary 
prevention.15  In the primary prevention settings, there is some 
debate as to when to prescribe aspirin, but a sensible approach 
would be to give aspirin to patients who are deemed high risk 
(e.g. diabetes) or who have a cardiovascular risk of more than 
5% ( for SCORE charts) or 20% (for Framingham charts) in the 
next ten years.
As regards statins, numerous trials have shown that they 
have a beneficial effect on the cardiovascular system which goes 
beyond the lipid lowering effect. In the context of secondary 
prevention it has been adequately shown that statins are 
beneficial even when cholesterol levels are within acceptable 
ranges.16
As regards primary prevention, again, prescribing should be 
guided by the cardiovascular risk since there is no consensus 
as to the lipid levels adequate for prescribing; the trend is that 
with each set of guidelines issued, the prescribing threshold is 
lowered further. However it sounds reasonable that patients 
with cardiovascular risk of less than 5% (SCORE) or 20% 
(Framingham) over the next ten years should be prescribed 
a statin, if their total cholesterol is >5.0 mmol/L or LDL-
cholesterol >3.0 mmol/L in the absence of a compensatory high 
HDL cholesterol level.
Blood pressure-lowering treatment
All major drug classes have been shown to be more or less 
equally effective in lowering blood pressure.17 The major benefit 
with the exception of particular situations is mostly derived from 
the actual blood pressure lowering, rather than the drug class 
used. In recent head-to-head comparisons β-blockers have done 
worse than all other drug classes and they are being side-lined 
as first line therapy except in certain situations such as angina 
or in the aftermath of myocardial infarction.18
The last few years have seen an array of trials being carried 
out with the intent of studying various drug classes and their 
beneficial effect.  There are still many heated debates about the 
preferred first line drug and whether to use drug combinations 
or not.
The issue of preferred first line treatment is slowly being 
clarified.  This issue is a non-issue in itself, since many patients 
will need more than one medication to effectively lower their BP. 
After the ALLHAT study, it was concluded that thiazides should 
be used as first line; 19 but recently there has been an increased 
awareness of the racial differences in hypertension, and such 
blanket statements are not very accurate.  In fact the most recent 
NICE guidelines have adopted the BHS 2004 model of A(B)CD 
(Figure 4), contrary to the JNC 7 and the ESH guidelines, both 
of which were issued in 2003. The A(B)CD model reflects the 
difference in response between individuals, due to different 
mechanisms causing hypertension; black people and elderly 
individuals tend to have low renin levels, and thus respond 
better to calcium channel blockers or thiazide diuretics; while 
younger people and white population tend to have high renin 
levels and respond better to RAS blockers such as angiotensin 
converting enzyme inhibitors (ACEI)  and angiotensin receptor 
blockers (ARBs). 
Further additions of drugs should be done according to 
recognized beneficial drug combinations (Figure 5).
As regards fixed drug combinations, they should ideally be 
used once the patient is stabilized and any side effects of the 
individual components monitored adequately. These fixed drug 
combinations certainly encourage compliance.
Table 2 summarizes the major indications and 
contraindications in line with recent evidence from trials. 
Moxonidine and Rilmenidine, are centrally acting agents 
which are useful especially in resistant hypertension.  Further 
longitudinal studies of mortality and morbidity are needed for 
both drugs. 
Follow-up
During follow up visits, it is important to cover a number 
of issues including:
a. Blood pressure response to treatment
b. Discuss side effects from medications
c. Encourage the patient to continue with a successful 
treatment plan
d. Look out for complications
e. Discuss any difficulties which may crop up.
As regards follow-up, this needs to be agreed with the 
patient.  Generally,people are now very conscious about 
hypertension, and in some cases, the concern verges on the 
obsessional.  There are no fixed time frames recommended 
for follow-up frequency and this depends on the individual 
case, with co-morbidities and need of laboratory tests usually 
influencing the frequency of visits.  
However, in routine cases it would be ideal to monitor 
at monthly intervals until the blood pressure settles to an 
acceptable level. High BP levels would warrant a more frequent 
initial review. Following attainment of the target blood 
pressure, it is recommended that follow-up visits should be 
carried out on a three-to-six month interval basis. There 
is no difference in control obtained between three month follow-
up or six month follow-up 20 and ultimately, individual clinical 
judgement should prevail.
In this particular case
Since MB has been confirmed to have hypertension through 
serial readings, it would be advisable to carry out some baseline 
biochemical assessment and ECG as outlined above. Once 
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the results are known, then treatment can be initiated.  It is 
important to emphasise the need of regular exercise and to 
adopt a healthy way of eating (small portions spread throughout 
the day and a diet low in salt and saturated fats). Her CVD risk 
is less than 5% for the next five years (SCORE charts). Hence 
there is no need to start aspirin. It would seem sensible to start 
MB on a calcium channel blocker (given the high systolic value) 
and proceed to combining it with an ACEI given that both of 
these drugs are lipid neutral. If she fails to lower her cholesterol 
through TLCs, one could give a low dose statin (e.g. simvastatin 
10mg) to lower her cholesterol and in so doing lower also her 
cardiovascular risk.
References
1. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ; 
Comparative Risk Assessment Collaborating Group. Selected 
major risk factors and global and regional burden of disease. 
Lancet. 2002 Nov 2;360(9343):1347-60
2. Kearney PM, Whelthon M, Reynolds K, Muntner P, Whelton PK, 
He J. Global burden of hypertension: analysis of worldwide data.. 
Lancet  2005; 365:217-23
3. Kannel WB. Blood Pressure as a cardiovascular risk factor: 
prevention and treatment. JAMA 1996; 275: 1571-6
4. Ogden LG, He J, Lydick E, Whelton PK. Long-term absolute 
benefit of lowering blood pressure in hypertensive patients 
according to the JNC VI risk stratification. Hypertension 2000; 
35: 539-43
5. Primatesta P, Brookes M, Poultner NR. Improved hypertension 
management and control: results from the health survey for 
England 1998. Hypertension 2001;38(4):827-32
6. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, 
Izzo JL et al. The Seventh Report of the Joint National Committee 
on Prevention, Detection, Evaluation and Treatment of High 
Blood Pressure: The JNC 7 Report. JAMA 2003;289:2560-72
7. Morris B. Hypertension and ethnic group. BMJ 2006;332:833-36
8. Practice Guidelines Writing Committee. Practice Guidelines for 
Primary Care Pysicians: 2003 ESH/ESC Hypertension Guidelines. 
J Hypertens 2003;21:10
9. Prospective Studies Collaboration. Age-specific relevance of 
usual BP to vascular mortality: a meta-analysis of individual 
data for one million adults in 61 prospective studies. Lancet 
2002;360:1903-1913
10. Third report of the National Cholesterol Education Programme 
(NCEP). Expert panel on detection, evaluation and treatment of 
high blood cholesterol in adults (ATP III) final report. Circulation 
2002;106:3143-421
11. Benson J, Britten N. Patients’ decisions about whether or 
not to take antihypertensive drugs: qualitative study. BMJ 
2002;325:873-8
12. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, 
Caulfield M, et al. Prevention of cardiovascular events with an 
antihypertensive regimen of amlodipine adding perindopril as 
required versus atenolol adding bendrofluazide as required in the 
Anglo Scandinavian Clinical Outcomes Trial – Blood Pressure 
Lowering Arm (ASCOT-BPLA): a multicentre randomized 
controlled trial. Lancet 2005:366;895-906
13. Mant J, McManus RJ, Hare R. Applicability to primary care of 
national guidelines on blood pressure lowering for people with 
stroke: cross sectional study. BMJ 2006;332:635-7
14. Little P, Margetts B. The importance of diet and physical activity 
in the treatment of conditions managed in general practice. BJGP 
1996;46:187-92
15. Antithrombotic Trialists’ Collaboration. Collaborative meta-
analysis of randomized trials of anti-platelet therapy for 
prevention of death, myocardial infarction and stroke in high risk 
patients. BMJ 2002;324:71
16. MRC/BHF Heart Protection Study Collaborative group. MRC/
BHF Heart Protection Study of cholesterol  lowering with 
Simvastatin in 20536 high risk individuals: a randomized placebo 
controlled trial. Lancet 2002;360:7-21
17. Blood Pressure Lowering treatment Trialists’ Collaboration. 
Effects of blood pressure lowering regimens on major 
cardiovascular events: results of prospectively designed overviews 
of randomized trials. Lancet 2003;362:1527-45
18. The National Collaborating Centre for Chronic Conditions. 
Hypertension – Management of hypertension in adults in primary 
care: partial update to NICE 2004. Available from http://www.
nice.org.uk
19. The ALLHAT Officers and Coordinators for the ALLHAT 
Collaborative Research Group. Major outcomes in high risk 
hypertensive patients randomized to angiotensin-converting 
enzyme inhibitor or calcium channel blocker vs diuretic: the 
antihypertensive and lipid-lowering treatment to prevent heart 
attack trial (ALLHAT). JAMA 2002;356:1955-64
20. Birtwhistle RV, Godwin MS, Delva MD,  Casson RI, Lam M, 
MacDonald SE, et al. Randomized equivalence trial comparing 
three month and six month follow-up of patients with 
hypertension by family practitioners. BMJ 2004; 328: 204-10
